Accessibility Menu
Cognetivity Neurosciences logo

Cognetivity Neurosciences(OTC) CGNSF

Current Price$0.00
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-99%
1 Month+0%
Cognetivity Neurosciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-06-25
Cognetivity Neurosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99%USD 0.002026-06-17
1 month+0%USD 0.002025-12-30
3 month+0%USD 0.002025-12-30
Year to date+0%USD 0.002025-12-30
1 year-99%USD 0.002025-04-14
3 year-100%USD 0.232023-06-26
5 year-100%USD 0.852021-06-25
Since inception-100%USD 0.352018-10-04

Cognetivity Neurosciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$98.97K

Net Income (TTM)

-CA$8.64M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-4.38 (Low)

Price

$0.00

Volume

24,500

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jul 2, 2026

CGNSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cognetivity Neurosciences

Cognetivity Neurosciences Ltd. is a healthcare firm focused on advanced cognitive assessment. The company has developed a sophisticated platform for cognitive testing, designed for diverse settings including medical facilities and individual consumers. Its primary goal is to identify early signs of cognitive impairment, aiding in the diagnosis of conditions like dementia.

Products and Services
  • Advanced cognitive assessment platform for medical and commercial use
  • OptiMind, a dedicated wellness application for cognitive health
  • Comprehensive evaluation of broad brain functions
Growth Outlook
  • Increasing demand for cognitive health solutions in aging populations
  • Expansion into new markets and partnerships with healthcare providers
  • Focus on research and development to enhance product offerings
Financial Highlights
  • Q3 2023 revenue of 29,156 CAD, a significant increase from previous quarters
  • Trailing twelve months (TTM) gross profit margin of 45.7%, indicating potential for profitability
  • Cash and cash equivalents decreased to 16,570 CAD in Q3 2023, highlighting liquidity challenges
Cognetivity Neurosciences Ltd. operates in the healthcare information services sector, emphasizing cognitive health. The company’s innovative platform is designed to detect cognitive impairment early, which is crucial for timely intervention. The recent quarterly revenue shows a positive trend, suggesting growing acceptance of its products. However, the financial data indicates challenges, particularly in cash flow management, which may impact operational capabilities. The focus on expanding market reach and enhancing product offerings through research and development could position the company favorably in the evolving healthcare landscape.
AI Generated • Jul 20, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Sina Habibi, PhD

Website

www.cognetivity.com

Headquarters

Vancouver, BC V6E 2E9, CA

CGNSF Financials

Key Financial Metrics (TTM)

Gross Margin

45.70%

Operating Margin

-14085.44%

Net Income Margin

-16386.72%

Return on Equity

95.52%

Return on Capital

N/A

Return on Assets

-262.74%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

24.50K

Avg. Volume

403.613

Financials (TTM)

Gross Profit

-CA$400.64K

Operating Income

-CA$4.42M

EBITDA

-CA$3.93M

Operating Cash Flow

-CA$3.85M

Capital Expenditure

-CA$28.56K

Free Cash Flow

-CA$3.88M

Cash & ST Invst.

CA$16.57K

Total Debt

CA$2.74M

Cognetivity Neurosciences Performance Analysis

Cognetivity Neurosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-01-31CAD 0N/A
20232023-01-31CAD 34,674N/A
Cognetivity Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-01-31N/A
Q12023-04-30-90.8%
Q22023-07-31387.0%
Q32023-10-3143.7%
Cognetivity Neurosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-01-31CAD -0.14N/A
20232023-01-31CAD -0.06-59.8%
Cognetivity Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-01-31-33.6%
Q12023-04-3018.5%
Q22023-07-319.8%
Q32023-10-31-3.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

CA$29.16K

N/A

Gross Profit

-CA$451.14K

-6821.4%

Gross Margin

-15.47%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2,500

N/A

Net Income

-CA$2.04M

-13.4%

EBITDA

-CA$700.29K

+59.2%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

CA$16.57K

-99.6%

Total Debt

CA$2.74M

+96.2%

Accounts Receivable

CA$251.78K

-52.9%

Inventory

CA$0.00

+100.0%

Long Term Debt

CA$1.37M

+10.2%

Short Term Debt

CA$1.37M

+794.9%

Return on Assets

-2.63%

N/A

Return on Invested Capital

82.30%

N/A

Free Cash Flow

-CA$1.69K

+99.3%

Operating Cash Flow

CA$16.94K

+107.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EMEDElectromedical Technologies, Inc.
$0.00+0.00%
EMYSFEasy Technologies Inc.
$0.02+0.00%
HPMMHemp Naturals, Inc.
$0.00+0.00%
SHWZMedicine Man Technologies, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.00-0.03%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$31.27-0.14%

Questions About CGNSF

What is the current price of Cognetivity Neurosciences?

Cognetivity Neurosciences is trading at $0.00 per share.

What is the 52-week range for Cognetivity Neurosciences?

Over the past 52 weeks, Cognetivity Neurosciences has traded between $0.00 and $0.00.

How much debt does Cognetivity Neurosciences have?

As of the most recent reporting period, Cognetivity Neurosciences reported total debt of CA$4.85M.

How much cash does Cognetivity Neurosciences have on hand?

Cognetivity Neurosciences reported CA$1.68M in cash and cash equivalents in its most recent financial results.

What is Cognetivity Neurosciences’s dividend yield?

Cognetivity Neurosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services